P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | N=30 --> 1

P1, N=60, Recruiting, Liping Dou

P2, N=40, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Mar 2027 --> Sep 2029 | Trial primary completion date: Mar 2026 --> Mar 2028

P1, N=54, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P1, N=57, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab in previously treated ES-SCLC generated an unprecedented response...Due to tumor heterogeneity and plasticity, rational combinations pursuing broader cancer cell vulnerabilities are likely necessary in the future to prevent relapse. Better tools for response monitoring are urgently needed to gauge progress.

We used ERY22, a T-cell engager developed as a monkey surrogate of the human therapeutic candidate ERY974, an anti-GPC3/CD3 T-cell engager...Interindividual variability in cytokine production and cytotoxicity correlated with chromatin accessibility at loci associated with these processes. These findings advance understanding of personalized risk prediction and management of CRS in clinical settings.

P3, N=570, Not yet recruiting, Astellas Pharma Global Development, Inc.

Vibecotamab was active in low-blast myeloid diseases, although the durability of responses was modest. Additional studies of CD123-targeting bispecific antibodies, alone or in combination, are warranted for these diseases.

These data provide new insights into Gαq-driven modulators of UM phenotype of relevance for studies of tumor-microenvironment interaction and metastasis.

Early monitoring and prompt supportive management during initial treatment cycles are essential. These findings broaden current knowledge of tarlatamab safety in real-world practice and support prospective studies to pharmacovigilance-based signal stratification and monitoring strategies.

We conducted a retrospective, single-center study including 27 patients with RRMM who were treated with bsAbs (teclistamab, elranatamab, or talquetamab) between June 2022 and September 2025 and for whom genetic material was available before bsAB treatment. These findings suggest that PPM1D mutations may represent a promising biomarker in patients with RRMM treated with bsAbs. Larger, prospective studies are warranted to validate and further elucidate these observations.